Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Nov 30;13(12):2405.
doi: 10.3390/v13122405.

Limited Impact of Delta Variant's Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population

Carlos A Sariol  1   2   3 , Crisanta Serrano-Collazo  2 , Edwin J Ortiz  2   4 , Petraleigh Pantoja  2 , Lorna Cruz  1   2 , Teresa Arana  1   2 , Dianne Atehortua  4 , Christina Pabon-Carrero  4 , Ana M Espino  1
Affiliations
Comparative Study

Limited Impact of Delta Variant's Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population

Carlos A Sariol et al. Viruses. .

Abstract

The SARS-CoV-2 pandemic has impacted public health systems all over the world. The Delta variant seems to possess enhanced transmissibility, but no clear evidence suggests it has increased virulence. Our data show that pre-exposed individuals had similar neutralizing activity against the authentic COVID-19 strain and the Delta and Epsilon variants. After only one vaccine dose, the neutralization capacity expanded to all tested variants in pre-exposed individuals. Healthy vaccinated individuals showed a limited breadth of neutralization. One vaccine dose did induce similar neutralizing antibodies against the Delta as against the authentic strain. However, even after two doses, this capacity only expanded to the Epsilon variant.

Keywords: COVID-19 vaccine; SARS-CoV-2; neutralization; protection; serology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Neutralization capacity of sera from infected and non-infected individuals against SARS-CoV-2 variants before and after vaccination. The neutralization activity of sera from infected individuals (n = 10) and non-infected ones (n = 21) before and after vaccination was evaluated against the six variants of concern. Dotted lines indicate the limit of detection of the sVNT assay, where the percentage of signal inhibition is determined (≥30% indicates a positive result). A normality test (Shapiro–Wilk) was performed for all datasets in order to assess the distribution of the data. The significance threshold for all analyses was set at p < 0.05. (A). Neutralization activity of sera from infected individuals (n = 10) before vaccination. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. (B). Neutralization activity of sera from healthy individuals (n = 21) after receiving the 1st vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. (C). Neutralization activity of sera from infected individuals (n = 10) after receiving the first vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. (D). Neutralization activity of sera from healthy individuals (n = 21) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants. (E). Neutralization activity of sera from infected individuals (n = 10) after receiving the 2nd vaccine dose. A one-way ANOVA test with Dunnett’s multiple comparisons test was performed between each of the variants. (F). Neutralization activity of sera from vaccinated individuals, pre-exposed (n = 10, depicted in circles) and healthy (n = 21, depicted in squares), after receiving the 2nd dose was evaluated. A one-way ANOVA test with Dunn’s Kruskal–Wallis multiple comparisons test was performed between each of the variants.
See this image and copyright information in PMC

Update of

References

    1. Cucinotta D., Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91:157–160. doi: 10.23750/abm.v91i1.9397. - DOI - PMC - PubMed
    1. Gavriatopoulou M., Ntanasis-Stathopoulos I., Korompoki E., Fotiou D., Migkou M., Tzanninis I.G., Psaltopoulou T., Kastritis E., Terpos E., Dimopoulos M.A. Emerging treatment strategies for COVID-19 infection. Clin. Exp. Med. 2021;21:167–179. doi: 10.1007/s10238-020-00671-y. - DOI - PMC - PubMed
    1. Di Gennaro F., Gualano G., Timelli L., Vittozzi P., Di Bari V., Libertone R., Cerva C., Pinnarelli L., Nisii C., Ianniello S., et al. Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. Antibiotics. 2021;10:272. doi: 10.3390/antibiotics10030272. - DOI - PMC - PubMed
    1. Erdmann F., Wellbrock M., Trübenbach C., Spix C., Schrappe M., Schüz J., Grabow D., Eichinger M. Impact of the COVID-19 pandemic on incidence, time of diagnosis and delivery of healthcare among paediatric oncology patients in Germany in 2020: Evidence from the German Childhood Cancer Registry and a qualitative survey. Lancet Reg. Health Eur. 2021;9:100188. doi: 10.1016/j.lanepe.2021.100188. - DOI - PMC - PubMed
    1. World Health Organization Coronavirus (COVID-19) Dashboard. [(accessed on 10 October 2021)]; Available online: https://covid19.who.int/

Publication types

Supplementary concepts